Y-biologics Inc.

Gi Sun Baek

Young Woo Park

Bum-chan Park

Seok Ho Yoo

Jae Eun Park

Young-Gyu Cho

Jung Chae Lim

Yeung Chul Kim

Si Hyung Lee

Jisu Lee

Hyun Mi Lee

Youngja Song

Sunha Yoon

Sang Pil Lee

Yunseon Choi

Ji-Young Shin

Soo A Choi

Eun Young Jeon

Bum-Chan Park

A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-α. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-α and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-α, it has an advantage of improving the treatment effect with lower dose.

Bispecific antibody specifically binding to IL-17A and TNF-α

The present invention relates to an antibody against delta-like 1 homolog () (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Antibody against human DLK1 and use thereof

Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.

Antibody to programmed death-ligand 1 (PD-L1) and use thereof

Growing community of inventors

Daejeon, South Korea

Gi Sun Baek